Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Nemolizumab in Subjects With Chronic Kidney Disease With Associated Moderate to Severe Pruritus

NCT05075408 is registered in ClinicalTrials.gov with Galderma R&D as lead sponsor.

NCT NCT05075408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05075408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Nemolizumab in Subjects With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
Lead sponsor
Galderma R&D
Phase
Phase 2/3
Overall status
Completed
Start date
March 18, 2022
Completion date
January 4, 2024
Enrollment
258 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease associated moderate to severe pruritus